Sugi Predict

Sugi Predict / Compounds / SCHEMBL4452913

SCHEMBL4452913

SCHEMBL4452913

COC[C@@H](NC(=O)OC(C)(C)C)C(=O)OC

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 11/20 0.50
▸ CTSK P43235 9/20 0.50
▸ CTSL P07711 3/20 0.50
▸ CTSB P07858 2/20 0.50
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ CAPN1 P07384 1/20 0.44
▸ NFKB1 P19838 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43
▸ KLK5 Q9Y337 1/20 0.42
▸ CA12 O43570 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10796111 1.00 CTSS (0.50) CTSSCTSKCTSLCTSBCYP1A2
SCHEMBL10796108 1.00 CTSS (0.50) CTSSCTSKCTSLCTSBCYP1A2
SCHEMBL1688822 0.93 CTSS (0.50) CTSSCTSKCTSLCTSBCYP1A2
SCHEMBL30695403 0.90 CTSS (0.46) CTSSCTSKCTSLCTSBCYP1A2
SCHEMBL12396372 0.88 CTSS (0.47) CTSSCTSKCTSLCTSBCYP1A2
SCHEMBL25886335 0.88 CTSS (0.47) CTSSCTSKCTSLCTSBCYP1A2
SCHEMBL23805193 0.88 CTSK (0.46) CTSSCTSKCTSLCTSBCYP1A2
SCHEMBL8372342 0.88 CTSK (0.46) CTSSCTSKCTSLCTSBCYP1A2
SCHEMBL2158515 0.88 CTSK (0.46) CTSSCTSKCTSLCTSBCYP1A2
SCHEMBL7505293 0.87 PPARA (0.43) CTSSCTSKCTSLCTSBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118812395-A Method for synthesizing lacosamide intermediate 浙江普洛家园药业有限公司 2024-10-22 — — CN claimed
US-12570675-B2 Boronic acid compounds LG CHEM, LTD. (KR) 2026-03-10 — — US disclosed
CN-118812395-A Method for synthesizing lacosamide intermediate 浙江普洛家园药业有限公司 2024-10-22 — — CN disclosed
CN-118812395-A Method for synthesizing lacosamide intermediate 浙江普洛家园药业有限公司 2024-10-22 — — CN disclosed
US-20240101579-A1 BORONIC ACID COMPOUNDS LG CHEM, LTD. (KR) 2024-03-28 — — US disclosed
EP-4242213-A1 BORONIC ACID COMPOUND Lg Chem, Ltd. (KR) 2023-09-13 — — EP disclosed
CN-116568310-A Boric acid compounds 株式会社LG化学 2023-08-08 — — CN disclosed
US-20230105745-A1 CYCLOALKYL AND HETERO-CYCLOALKYL INHIBITORS, PREPARATION METHODS THEREFOR, AND USE THEREOF SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) 2023-04-06 — — US disclosed
CN-115594680-A TEAD inhibitor 武汉人福创新药物研发中心有限公司（CN） 2023-01-13 — — CN disclosed
WO-2023280254-A1 TEAD INHIBITOR 武汉人福创新药物研发中心有限公司 2023-01-12 — — WO disclosed
US-20170044182-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. 2017-02-16 — — US disclosed
US-20170044182-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. 2017-02-16 — — US disclosed
US-20170044182-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. 2017-02-16 — — US disclosed
WO-2015109109-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. (US) 2015-07-23 — — WO disclosed
WO-2015109109-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. (US) 2015-07-23 — — WO disclosed
US-7632840-B2 Quinazoline compounds for the treatment of hyperproliferative disorders ASTRAZENECA AB (SE) 2009-12-15 — — US disclosed
EP-1713781-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2008-11-05 — — EP disclosed
US-20070293490-A1 Quinazoline Derivatives ASTRAZENECA AB (SE) 2007-12-20 — — US disclosed
EP-1713781-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2006-10-25 — — EP disclosed
WO-2005075439-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230105745-A1 CYCLOALKYL AND HETERO-CYCLOALKYL INHIBITORS, PREPARATION METHODS THEREFOR, AND USE THEREOF KRAS, NRAS, WEE1 CTSS 402/4885CTSK 1484/4885CTSL 310/4885
US-12570675-B2 Boronic acid compounds PSMB6, PSMB3, PSMB2 CTSS 1505/4885CTSK 1682/4885CTSL 1540/4885
US-20170044182-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF SMN1; SMN2, FUS, SYNCRIP CTSS 4147/4885CTSK 4174/4885CTSL 4523/4885
US-20070293490-A1 Quinazoline Derivatives CCNA1, CCND3, CCND2 CTSS 3079/4885CTSK 1447/4885CTSL 1808/4885
US-20240101579-A1 BORONIC ACID COMPOUNDS PSMB11, PSMB1, BACH1 CTSS 2423/4885CTSK 2553/4885CTSL 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.